LPCN News and Press, Lipocine Inc. From 01/18/24

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada PR Newswire Lipocine to receive $11 million license fee Up to $259 million in development and commercial sales milestones Tiered royalties on net sales of ...

Lipocine to Present at Biotech Showcase 2024 PR Newswire Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Dec. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on ...

2023-11-22 16:25:56 ET Lipocine ( NASDAQ: LPCN ) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Lipocine files for $150M ...

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 PR Newswire Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo to LPCN 1148 in the ongoing open lab...

2023-11-08 08:43:25 ET Lipocine press release ( NASDAQ: LPCN ): Q3 GAAP EPS of -$1.27 misses by $0.67 . As of September 30, 2023, Lipocine had $23.8 million of unrestricted cash, cash equivalents and marketable investment securities compared to $32.5 million at Decembe...

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 PR Newswire SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by l...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Lipocine Inc. (LPCN) is expected to report $-0.57 for Q3 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 PR Newswire "Late Breaking" abstract scheduled for oral presentation on November 13 SALT LAKE CITY , Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceuti...

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression PR Newswire Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initia...